FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1910050651> ?p ?o ?g. }

• W1910050651 endingPage "1027" @default.
• W1910050651 startingPage "1027" @default.
• W1910050651 abstract "<h3>Importance</h3> To reduce the amount of skin surface bacteria for patients undergoing elective surgery, selective health care facilities have instituted a preadmission antiseptic skin cleansing protocol using chlorhexidine gluconate. A Cochrane Collaborative review suggests that existing data do not justify preoperative skin cleansing as a strategy to reduce surgical site infection. <h3>Objectives</h3> To develop and evaluate the efficacy of a standardized preadmission showering protocol that optimizes skin surface concentrations of chlorhexidine gluconate and to compare the findings with the design and methods of published studies on preoperative skin preparation. <h3>Design, Setting, and Participants</h3> A randomized prospective analysis in 120 healthy volunteers was conducted at an academic tertiary care medical center from June 1, 2014, to September, 30, 2014. Data analysis was performed from October 13, 2014, to October 27, 2014. A standardized process of dose, duration, and timing was used to maximize antiseptic skin surface concentrations of chlorhexidine gluconate applied during preoperative showering. The volunteers were randomized to 2 chlorhexidine gluconate, 4%, showering groups (2 vs 3 showers), containing 60 participants each, and 3 subgroups (no pause, 1-minute pause, or 2-minute pause before rinsing), containing 20 participants each. Volunteers used 118 mL of chlorhexidine gluconate, 4%, for each shower. Skin surface concentrations of chlorhexidine gluconate were analyzed using colorimetric assay at 5 separate anatomic sites. Individual groups were analyzed using paired<i>t</i>test and analysis of variance. <h3>Intervention</h3> Preadmission showers using chlorhexidine gluconate, 4%. <h3>Main Outcomes and Measures</h3> The primary outcome was to develop a standardized approach for administering the preadmission shower with chlorhexidine gluconate, 4%, resulting in maximal, persistent skin antisepsis by delineating a precise dose (volume) of chlorhexidine gluconate, 4%; duration (number of showers); and timing (pause) before rinsing. <h3>Results</h3> The mean (SD) composite chlorhexidine gluconate concentrations were significantly higher (<i>P</i> < .001) in the 1- and 2-minute pause groups compared with the no-pause group in participants taking 2 (978.8 [234.6], 1042.2 [219.9], and 265.6 [113.3] µg/mL, respectively) or 3 (1067.2 [205.6], 1017.9 [227.8], and 387.1 [217.5] µg/mL, respectively) showers. There was no significant difference in concentrations between 2 and 3 showers or between the 1- and 2-minute pauses. <h3>Conclusions and Relevance</h3> A standardized preadmission shower regimen that includes 118 mL of aqueous chlorhexidine gluconate, 4%, per shower; a minimum of 2 sequential showers; and a 1-minute pause before rinsing results in maximal skin surface (16.5 µg/cm²) concentrations of chlorhexidine gluconate that are sufficient to inhibit or kill gram-positive or gram-negative surgical wound pathogens. This showering regimen corrects deficiencies present in current nonstandardized preadmission shower protocols for patients undergoing elective surgery." @default.
• W1910050651 created "2016-06-24" @default.
• W1910050651 creator A5001986585 @default.
• W1910050651 creator A5008405410 @default.
• W1910050651 creator A5014575450 @default.
• W1910050651 creator A5016379741 @default.
• W1910050651 creator A5033233412 @default.
• W1910050651 creator A5042655474 @default.
• W1910050651 creator A5049949901 @default.
• W1910050651 creator A5081583029 @default.
• W1910050651 creator A5083385442 @default.
• W1910050651 creator A5085481325 @default.
• W1910050651 date "2015-11-01" @default.
• W1910050651 modified "2023-10-02" @default.
• W1910050651 title "Evidence for a Standardized Preadmission Showering Regimen to Achieve Maximal Antiseptic Skin Surface Concentrations of Chlorhexidine Gluconate, 4%, in Surgical Patients" @default.
• W1910050651 cites W140517158 @default.
• W1910050651 cites W1822698786 @default.
• W1910050651 cites W1889227901 @default.
• W1910050651 cites W1969493214 @default.
• W1910050651 cites W1978301414 @default.
• W1910050651 cites W1979345361 @default.
• W1910050651 cites W1987160293 @default.
• W1910050651 cites W2002542099 @default.
• W1910050651 cites W2005681599 @default.
• W1910050651 cites W2020236756 @default.
• W1910050651 cites W2034721275 @default.
• W1910050651 cites W2038204338 @default.
• W1910050651 cites W2042898216 @default.
• W1910050651 cites W2057623533 @default.
• W1910050651 cites W2059526358 @default.
• W1910050651 cites W2066174441 @default.
• W1910050651 cites W2076379755 @default.
• W1910050651 cites W2078144642 @default.
• W1910050651 cites W2080766724 @default.
• W1910050651 cites W2087226482 @default.
• W1910050651 cites W2096583086 @default.
• W1910050651 cites W2100023648 @default.
• W1910050651 cites W2103954882 @default.
• W1910050651 cites W2114304769 @default.
• W1910050651 cites W2117883860 @default.
• W1910050651 cites W2122626516 @default.
• W1910050651 cites W2123764051 @default.
• W1910050651 cites W2150900933 @default.
• W1910050651 cites W2153416135 @default.
• W1910050651 cites W2156210975 @default.
• W1910050651 cites W2157715904 @default.
• W1910050651 cites W2159970099 @default.
• W1910050651 cites W2168843978 @default.
• W1910050651 cites W2169860676 @default.
• W1910050651 cites W2322599067 @default.
• W1910050651 cites W2491506870 @default.
• W1910050651 cites W44422039 @default.
• W1910050651 doi "https://doi.org/10.1001/jamasurg.2015.2210" @default.
• W1910050651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26308490" @default.
• W1910050651 hasPublicationYear "2015" @default.
• W1910050651 type Work @default.
• W1910050651 sameAs 1910050651 @default.
• W1910050651 citedByCount "69" @default.
• W1910050651 countsByYear W19100506512015 @default.
• W1910050651 countsByYear W19100506512016 @default.
• W1910050651 countsByYear W19100506512017 @default.
• W1910050651 countsByYear W19100506512018 @default.
• W1910050651 countsByYear W19100506512019 @default.
• W1910050651 countsByYear W19100506512020 @default.
• W1910050651 countsByYear W19100506512021 @default.
• W1910050651 countsByYear W19100506512022 @default.
• W1910050651 countsByYear W19100506512023 @default.
• W1910050651 crossrefType "journal-article" @default.
• W1910050651 hasAuthorship W1910050651A5001986585 @default.
• W1910050651 hasAuthorship W1910050651A5008405410 @default.
• W1910050651 hasAuthorship W1910050651A5014575450 @default.
• W1910050651 hasAuthorship W1910050651A5016379741 @default.
• W1910050651 hasAuthorship W1910050651A5033233412 @default.
• W1910050651 hasAuthorship W1910050651A5042655474 @default.
• W1910050651 hasAuthorship W1910050651A5049949901 @default.
• W1910050651 hasAuthorship W1910050651A5081583029 @default.
• W1910050651 hasAuthorship W1910050651A5083385442 @default.
• W1910050651 hasAuthorship W1910050651A5085481325 @default.
• W1910050651 hasBestOaLocation W19100506511 @default.
• W1910050651 hasConcept C126322002 @default.
• W1910050651 hasConcept C141071460 @default.
• W1910050651 hasConcept C142724271 @default.
• W1910050651 hasConcept C168563851 @default.
• W1910050651 hasConcept C199343813 @default.
• W1910050651 hasConcept C2777084678 @default.
• W1910050651 hasConcept C2781413609 @default.
• W1910050651 hasConcept C2781460226 @default.
• W1910050651 hasConcept C2991686891 @default.
• W1910050651 hasConcept C535046627 @default.
• W1910050651 hasConcept C71924100 @default.
• W1910050651 hasConceptScore W1910050651C126322002 @default.
• W1910050651 hasConceptScore W1910050651C141071460 @default.
• W1910050651 hasConceptScore W1910050651C142724271 @default.
• W1910050651 hasConceptScore W1910050651C168563851 @default.
• W1910050651 hasConceptScore W1910050651C199343813 @default.
• W1910050651 hasConceptScore W1910050651C2777084678 @default.
• W1910050651 hasConceptScore W1910050651C2781413609 @default.
• W1910050651 hasConceptScore W1910050651C2781460226 @default.

• next